Crotamiton
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Crotamiton: From Scabies to Trombiculiasis
One-Sentence Summary
Crotamiton is a topical acaricide (mite-killing agent) historically used to treat scabies caused by Sarcoptes scabiei infestation. The TxGNN model predicts it may be effective for Trombiculiasis (chigger mite infestation), with 0 clinical trials and 0 publications currently supporting this specific direction — evidence is at the earliest exploratory stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Scabies (mite infestation of skin) |
| Predicted New Indication | Trombiculiasis (chigger mite infestation) |
| TxGNN Prediction Score | 96.24% |
| Evidence Level | L5 |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Research Question |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacological information, Crotamiton is a topical acaricide (mite-killing agent) whose core approved indication is scabies — a skin infestation caused by the mite Sarcoptes scabiei. Its antipruritic (itch-relieving) and acaricidal properties form the pharmacological foundation of its use.
Trombiculiasis is caused by larvae of chigger mites (family Trombiculidae), which temporarily attach to human skin, inject digestive enzymes, and cause intense itching and local inflammation. Both Sarcoptes scabiei (scabies) and chigger mites belong to the class Arachnida, order Acari — the mechanistic link is therefore taxonomically grounded. A drug that kills one type of skin mite may plausibly affect another from the same biological order.
However, there is an important clinical difference: chigger larvae detach from the host naturally within a few days, meaning treatment goals for trombiculiasis are primarily symptomatic (itch relief) rather than eradicating an established infestation. Crotamiton's antipruritic activity — independent of its acaricidal activity — may be the more immediately relevant mechanism here. No clinical trials or literature currently support this repurposing hypothesis; the rating as a "Research Question" reflects pharmacological plausibility alone.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
Crotamiton has no registered products in Singapore. No authorization records are available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Research Question
Rationale: The mechanistic link between Crotamiton's established acaricidal activity in scabies and its potential utility in trombiculiasis is biologically plausible — both conditions involve Acari-class mite species — but no clinical or published evidence exists to support advancing this hypothesis beyond initial exploration.
To proceed, the following is needed:
- Confirm Crotamiton's precise mechanism of action (MOA) against mite species beyond S. scabiei, specifically against Trombiculidae larvae
- Conduct a structured literature search for any in vitro or in vivo acaricidal data on Crotamiton against chigger mites
- Review safety and skin tolerance data from existing scabies use to assess suitability for trombiculiasis application sites
- Clarify the primary treatment goal: if purely antipruritic (symptom relief), existing safety data from scabies use may partially support off-label topical use with appropriate informed consent
- Register the drug in Singapore before any local clinical evaluation can proceed
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.